This company has been acquired
F-star Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-39.9%
Tasa de crecimiento de los beneficios
4.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | -7.9% |
| Rentabilidad financiera | -78.6% |
| Margen neto | -211.3% |
| Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
F-star Therapeutics: Running Into A National Security Roadblock
Sep 22F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale
Sep 15F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Jul 29F-star enters license deal with Takeda for a cancer immune therapy antibody
Jul 20Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues
May 18
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results
Mar 17These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts
Mar 16F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
Jan 27F-star Therapeutics under pressure on pricing $65M stock offering
May 07Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like
Mar 17Merck KGaA discloses 5.4% stake in F-star Therapeutics
Feb 02Dosing underway in early-stage study of F-star's FS120 in cancer
Dec 03Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero F-star Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 22 | 21 | -45 | 21 | 35 |
| 30 Jun 22 | 21 | -37 | 21 | 30 |
| 31 Mar 22 | 21 | -34 | 22 | 30 |
| 31 Dec 21 | 21 | -31 | 23 | 29 |
| 30 Sep 21 | 4 | -45 | 20 | 24 |
| 30 Jun 21 | 12 | -37 | 22 | 24 |
| 31 Mar 21 | 13 | -28 | 19 | 18 |
| 31 Dec 20 | 11 | -26 | 15 | 14 |
| 30 Sep 20 | 13 | -23 | 19 | 22 |
| 30 Jun 20 | 5 | -25 | 17 | 27 |
| 31 Mar 20 | 17 | -24 | 16 | 30 |
| 31 Dec 19 | 28 | -23 | 15 | 31 |
| 31 Dec 18 | 38 | 17 | 1 | 0 |
| 31 Dec 17 | 15 | 5 | 1 | 0 |
Ingresos de calidad: FSTX is currently unprofitable.
Margen de beneficios creciente: FSTX is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: FSTX is unprofitable, and losses have increased over the past 5 years at a rate of 39.9% per year.
Acelerando crecimiento: Unable to compare FSTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: FSTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.4%).
Rentabilidad financiera
Alta ROE: FSTX has a negative Return on Equity (-78.59%), as it is currently unprofitable.